- Home
- PLRX
as 02-21-2025 4:00pm EST
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
Upcoming Earnings Alert:
Get ready for potential market movements as Pliant Therapeutics Inc. PLRX prepares to release earnings report on 26 Feb 2025.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 165.5M | IPO Year: | 2020 |
| Target Price: | $14.86 | AVG Volume (30 days): | 3.4M |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.43 - $18.00 | Next Earning Date: | 02-26-2025 |
| Revenue: | N/A | Revenue Growth: | -83.69% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Pliant Therapeutics Inc. (PLRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lefebvre Eric | PLRX | Chief Medical Officer | Jan 17 '25 | Sell | $11.20 | 18,478 | $206,973.93 | 194,574 | |
| Coulie Bernard | PLRX | President and CEO | Jan 17 '25 | Sell | $11.20 | 52,419 | $587,150.46 | 430,517 | |
| Ouimette Mike | PLRX | General Counsel & Corp. Sec'y | Jan 17 '25 | Sell | $11.10 | 23,500 | $261,101.08 | 80,774 | |
| Cummings Keith Lamont | PLRX | Chief Financial Officer | Jan 17 '25 | Sell | $11.20 | 20,148 | $225,679.76 | 262,608 | |
| Hull Hans | PLRX | Chief Business Officer | Jan 17 '25 | Sell | $11.20 | 15,936 | $178,500.73 | 211,558 | |
| Cheung Lily | PLRX | Chief Human Resource Officer | Jan 17 '25 | Sell | $11.20 | 3,740 | $41,892.11 | 24,550 |
Latest Pliant Therapeutics Inc. News
PLRX Breaking Stock News: Dive into PLRX Ticker-Specific Updates for Smart Investing
Simply Wall St.
4 days ago
Blade Air Mobility Leads The Charge Among 3 US Penny Stocks
Zacks
8 days ago
All You Need to Know About PLIANT THERAPT (PLRX) Rating Upgrade to Buy
MT Newswires
8 days ago
Sector Update: Health Care Stocks Advance Late Afternoon
MT Newswires
9 days ago
Pliant Therapeutics to Assemble Expert Panel to Review BEACON-IPF Trial Data; Shares Jump
BioPharma Dive
9 days ago
Neumora shakes up its C-suite; Biogen cuts early-stage pipeline
GlobeNewswire
9 days ago
Pliant Therapeutics Announces Next Steps Following DSMB Recommendation on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
TipRanks
11 days ago
Pliant Therapeutics downgraded to Neutral from Overweight at JPMorgan
MT Newswires
12 days ago
Sector Update: Health Care Stocks Retreat Monday Afternoon
Compare PLRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PLRX Pliant Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.